文章摘要
王婷,吴文晓,马全涛,耿兴超,李波.肝癌早期诊断标志物的研究进展[J].中国药事,2020,34(3):349-356
肝癌早期诊断标志物的研究进展
Progress in Biomarkers for Early Diagnosis of Hepatocellular Harcinoma
投稿时间:2019-05-21  
DOI:10.16153/j.1002-7777.2020.03.016
中文关键词: 肝癌  早期诊断  生物标志物  circRNA  miRNA
英文关键词: hepatocellular carcinoma  early diagnosis  biomarkers  circRNA  miRNA
基金项目:国家"重大新药创制"科技重大专项资助项目(编号2018ZX09201017-001,2018ZX09101002-002-002)
作者单位E-mail
王婷 中国食品药品检定研究院, 北京 100176  
吴文晓 中国食品药品检定研究院, 北京 100176
北京协和医学院, 北京 100005 
 
马全涛 北京中医药大学中药学院, 北京 100029  
耿兴超 中国食品药品检定研究院, 北京 100176 gengxch@nifdc.org.cn 
李波 中国食品药品检定研究院, 北京 100176 libo@nifdc.org.cn 
摘要点击次数: 1098
全文下载次数: 198
中文摘要:
      肝癌是全球最常见的恶性肿瘤之一,在我国的发病率和死亡率均很高,严重威胁着人类的健康。原发性肝癌早期不易发现,临床确诊时往往已发展至中晚期,治疗难度大且预后差。因此,早发现、早诊断、早治疗是提高原发性肝癌患者生存率的最佳途径。血清甲胎蛋白(AFP)是目前临床应用最广的肝癌诊断标记物,但在肝癌早期阶段敏感性和特异性不足,且部分肝癌患者AFP阴性,因此,需要寻找更有价值的肝癌早期诊断标志物。本文通过对肝癌早期诊断标志物研究现状的分析和思考,以期为肝癌早期诊断提供科学依据。
英文摘要:
      Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. The incidence and mortality of HCC in China are very high, which have severely threatened human health. Primary liver cancer (PHC) is difficult to detect in the early stage and often develops to the middle and advanced stage when it is diagnosed. Therefore, the treatment is difficult, and the prognosis is very poor. Accordingly, early detection, early diagnosis and early treatment are the best ways to improve the survival rate of patients with PHC. Serum Alphafetoprotein(AFP) is the most widely used diagnostic marker of HCC at present, but the sensitivity and specificity of AFP are insufficient in the early stage of HCC, and some patients with liver cancer are AFP negative. It is necessary to find more valuable biomarkers for early diagnosis of liver cancer. In this paper, the research status of early diagnosis biomarkers of HCC is analyzed and summarized in order to lay a scientific basis for early diagnosis of liver cancer.
查看全文   查看/发表评论  下载PDF阅读器
关闭